Group 1 - The core viewpoint of the news highlights that Tailin Bio's stock closed at 21.03 yuan, down 1.73%, with a rolling PE ratio of 238.08 times, and a total market value of 2.549 billion yuan [1] - In terms of industry comparison, the average PE ratio for the medical device industry is 51.05 times, with a median of 36.62 times, placing Tailin Bio at the 117th position [1][3] - The net outflow of main funds for Tailin Bio on July 4 was 2.3092 million yuan, with a total outflow of 23.9872 million yuan over the past five days [1] Group 2 - Tailin Bio specializes in the research, production, and promotion of products related to microbiological testing and pollution control, innovative drug development, and process analysis, serving various industries including biomedicine, healthcare, food and beverage, and environmental protection [2] - The latest quarterly report for Q1 2025 shows that the company achieved an operating income of 66.939 million yuan, a year-on-year decrease of 16.33%, and a net profit of 3.5282 million yuan, down 39.93%, with a sales gross margin of 49.27% [2]
泰林生物收盘下跌1.73%,滚动市盈率238.08倍,总市值25.49亿元